[go: up one dir, main page]

WO2024077273A3 - Compounds, compositions, and methods - Google Patents

Compounds, compositions, and methods Download PDF

Info

Publication number
WO2024077273A3
WO2024077273A3 PCT/US2023/076291 US2023076291W WO2024077273A3 WO 2024077273 A3 WO2024077273 A3 WO 2024077273A3 US 2023076291 W US2023076291 W US 2023076291W WO 2024077273 A3 WO2024077273 A3 WO 2024077273A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
compounds
sarm1
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/076291
Other languages
French (fr)
Other versions
WO2024077273A2 (en
Inventor
Lydia A. Auch
Alex L. BAGDASARIAN
Cyril Bucher
II Robert A. CRAIG
Javier De Vicente Fidalgo
Anthony A. ESTRADA
Brian M. Fox
Benjamin J. HUFFMAN
Katrina W. Lexa
Takashi Miyamoto
Arun THOTTUMKARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Priority to EP23875875.9A priority Critical patent/EP4598927A2/en
Priority to CN202380082414.0A priority patent/CN120641418A/en
Publication of WO2024077273A2 publication Critical patent/WO2024077273A2/en
Publication of WO2024077273A3 publication Critical patent/WO2024077273A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates generally to small molecule inhibitors of Sterile Alpha and TIR Motif containing 1 (SARM1) protein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
PCT/US2023/076291 2022-10-07 2023-10-06 Compounds, compositions, and methods Ceased WO2024077273A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP23875875.9A EP4598927A2 (en) 2022-10-07 2023-10-06 Compounds, compositions, and methods
CN202380082414.0A CN120641418A (en) 2022-10-07 2023-10-06 Compounds, compositions and methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263378842P 2022-10-07 2022-10-07
US63/378,842 2022-10-07
US202363580955P 2023-09-06 2023-09-06
US63/580,955 2023-09-06

Publications (2)

Publication Number Publication Date
WO2024077273A2 WO2024077273A2 (en) 2024-04-11
WO2024077273A3 true WO2024077273A3 (en) 2024-06-20

Family

ID=90608940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/076291 Ceased WO2024077273A2 (en) 2022-10-07 2023-10-06 Compounds, compositions, and methods

Country Status (3)

Country Link
EP (1) EP4598927A2 (en)
CN (1) CN120641418A (en)
WO (1) WO2024077273A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124609A1 (en) * 2006-07-14 2009-05-14 Amgen Inc. Fused heterocyclic derivatives and methods of use
WO2018098499A1 (en) * 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US20180222911A1 (en) * 2015-08-07 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124609A1 (en) * 2006-07-14 2009-05-14 Amgen Inc. Fused heterocyclic derivatives and methods of use
US20180222911A1 (en) * 2015-08-07 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018098499A1 (en) * 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LANGE, J ET AL.: "Bicyclic [b]-Heteroannelated Pyridazine Derivatives. Part 8. A Structure-Activity Relationship Study of the 6-Aryltriazolo[4,3-B]Pyridazine Ligands of the Benzodiazepine Receptor and its omega1 Subunit", ACTA POLONIA PHAMACEUTICA - DRUG RESEARCH, vol. 56, no. 1, 1 January 1999 (1999-01-01), PL , pages 61 - 68, XP009555651, ISSN: 0001-6837 *
OBOH EDMUND, SCHUBERT TANNER J., TEIXEIRA JOSE E., STEBBINS ERIN E., MILLER PETER, PHILO EMILY, THAKELLAPALLI HARESH, CAMPBELL SCO: "Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 15, 12 August 2021 (2021-08-12), US , pages 11729 - 11745, XP093186668, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.1c01136 *
THOMAS MICHAEL, BRAND STEPHEN, DE RYCKER MANU, ZUCCOTTO FABIO, LUKAC IVA, DODD PETER G., KO EUN-JUNG, MANTHRI SUJATHA, MCGONAGLE K: "Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 9, 13 May 2021 (2021-05-13), US , pages 5905 - 5930, XP093097316, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.1c00047 *

Also Published As

Publication number Publication date
WO2024077273A2 (en) 2024-04-11
CN120641418A (en) 2025-09-12
EP4598927A2 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
MX2023001757A (en) Compounds, compositions and methods.
WO2023168298A3 (en) Compounds, compositions, and methods
MX2023005906A (en) Compounds, compositions, and methods.
MXPA02005536A (en) New aminopropylphosphinic acids.
AR031828A2 (en) PROCEDURES FOR THE PREPARATION OF SPIRO-AZABICICLIC COMPOUNDS USEFUL IN THERAPY
WO2001028996A3 (en) Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases
WO2003048116A3 (en) Esters and amides as ppar-alpha agonists ____________
MX2023000001A (en) Compounds, compositions and methods.
DOP2024000146A (en) PARP7 INHIBITORS
MX2024011738A (en) COMPOUNDS, COMPOSITIONS AND METHODS
SE9904507D0 (en) New compounds
WO2024249901A3 (en) Compounds, compositions, and methods
WO2024249929A3 (en) Compounds, compositions, and methods
WO2025019357A3 (en) Compounds, compositions, and methods
WO2024077273A3 (en) Compounds, compositions, and methods
EP0322184B1 (en) N-(2-alkyl-3-mercapto-1,5-di-oxoalkyl)glycinamide derivatives and their use as collagenase inhibitors
WO2023240084A3 (en) Compounds, compositions, and methods
EA202192530A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS
IL166513A0 (en) Lamellarin derivatives and pharmaceutical compositions containing the same
WO2024130166A3 (en) Compounds, compositions, and methods
AR029629A1 (en) CEFAIBOLES, NEW ANTIPARASITES OBTAINED FROM ACREMONIUM TUBAKI, PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR THE PREPARATION AND USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT.
HUT52477A (en) Process for producing substituted pyrrolidine-2-carboxylic acid derivatives and pharmaceutical compositions comprising such compounds
ZA202403230B (en) Bicyclic amine derivatives as gabaa α5 receptor modulators
AR033779A1 (en) USEFUL COMPOUNDS IN REFLUX DISEASE
MX2023002970A (en) Antitumoral ascorbic acid esters.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23875875

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2023875875

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023875875

Country of ref document: EP

Effective date: 20250507

WWE Wipo information: entry into national phase

Ref document number: CN2023800824140

Country of ref document: CN

Ref document number: 202380082414.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2023875875

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 202380082414.0

Country of ref document: CN